"Chemokine CXCL12" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CXC chemokine that is chemotactic for T-LYMPHOCYTES and MONOCYTES. It has specificity for CXCR4 RECEPTORS. Two isoforms of CXCL12 are produced by alternative mRNA splicing.
| Descriptor ID |
D054377
|
| MeSH Number(s) |
D12.644.276.374.200.120.600 D12.776.467.374.200.120.600 D23.125.300.120.600 D23.469.200.120.600 D23.529.374.200.120.600
|
| Concept/Terms |
Chemokine CXCL12- Chemokine CXCL12
- CXCL12, Chemokine
- Stromal Cell-Derived Factor 1
- Stromal Cell Derived Factor 1
- CXCL12 Chemokine
- Chemokine, CXCL12
- Chemokine (C-X-C Motif) Ligand 12
- Pre-B-Cell Growth-Stimulating Factor
- Growth-Stimulating Factor, Pre-B-Cell
- Pre B Cell Growth Stimulating Factor
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL12".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL12".
This graph shows the total number of publications written about "Chemokine CXCL12" by people in this website by year, and whether "Chemokine CXCL12" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 5 | 5 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CXCL12" by people in Profiles.
-
Luo J, De Pascali F, Richmond GW, Khojah AM, Benovic JL. Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4. J Biol Chem. 2022 02; 298(2):101551.
-
Sanfilippo C, Castrogiovanni P, Imbesi R, Nunnari G, Di Rosa M. Postsynaptic damage and microglial activation in AD patients could be linked CXCR4/CXCL12 expression levels. Brain Res. 2020 12 15; 1749:147127.
-
Guerra K, Bryan C, Dapaah-Siakwan F, Sammour I, Drummond S, Zambrano R, Chen P, Huang J, Sharma M, Shrager S, Benny M, Wu S, Young KC. Intra-tracheal administration of a naked plasmid expressing stromal derived factor-1 improves lung structure in rodents with experimental bronchopulmonary dysplasia. Respir Res. 2019 Nov 12; 20(1):255.
-
Hersh TA, Dimond AL, Ruth BA, Lupica NV, Bruce JC, Kelley JM, King BL, Lutton BV. A role for the CXCR4-CXCL12 axis in the little skate, Leucoraja erinacea. Am J Physiol Regul Integr Comp Physiol. 2018 08 01; 315(2):R218-R229.
-
Alexeev V. CXCL12 as a Predictor of Vitiligo Activity and Disease Progression. J Invest Dermatol. 2017 07; 137(7):1588-1590.
-
Rezk AF, Kemp DM, El-Domyati M, El-Din WH, Lee JB, Uitto J, Igoucheva O, Alexeev V. Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and?Progression. J Invest Dermatol. 2017 05; 137(5):1126-1134.
-
Iinuma S, Aikawa E, Tamai K, Fujita R, Kikuchi Y, Chino T, Kikuta J, McGrath JA, Uitto J, Ishii M, Iizuka H, Kaneda Y. Transplanted bone marrow-derived circulating PDGFRa+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft. J Immunol. 2015 Feb 15; 194(4):1996-2003.
-
Perdoni C, McGrath JA, Tolar J. Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa. Stem Cell Res Ther. 2014 Nov 06; 5(6):121.
-
Geherin SA, Wilson RP, Jennrich S, Debes GF. CXCR4 is dispensable for T cell egress from chronically inflamed skin via the afferent lymph. PLoS One. 2014; 9(4):e95626.
-
Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res. 2013 Dec 15; 19(24):6957-66.